A Dark Vector Cognition product

Item 1. FINANCIAL STATEMENTS

165K characters. Original on sec.gov ·

Item 1. FINANCIAL STATEMENTS

The 38 tables in Item 1. FINANCIAL STATEMENTS as one CSV, figures in aligned columns. For subscribers: paste your API key. One API call. Plans from $19 a month, see pricing.

The Cigna Group Consolidated Statements of Income
UnauditedUnaudited
Three Months Ended September 30,Nine Months Ended September 30,
(In millions, except per share amounts)2026202520262025
Revenues
Pharmacy revenues$58,982$56,054$170,191$158,336
Premiums9,8859,08129,55630,973
Fees and other revenues4,5294,38013,33712,412
Net investment income287233761707
TOTAL REVENUES73,68369,748213,845202,428
Benefits and expenses
Pharmacy and other service costs58,59055,530169,393157,196
Medical costs and other benefit expenses8,4967,84224,85026,089
Selling, general and administrative expenses3,6123,36210,80411,008
Amortization of acquired intangible assets5894361,3681,280
TOTAL BENEFITS AND EXPENSES71,28767,170206,415195,573
Income from operations2,3962,5787,4306,855
Interest expense and other(333)(347)(1,046)(1,046)
Gain on sale of businesses—381779
Net investment gains362622576
Income before income taxes2,0992,2956,6265,964
TOTAL INCOME TAXES4013221,192950
Net income1,6981,9735,4345,014
Less: Net income attributable to noncontrolling interests256105678291
SHAREHOLDERS' NET INCOME$1,442$1,868$4,756$4,723
Shareholders' net income per share
Basic$5.49$7.02$18.09$17.65
Diluted$5.47$6.98$18.02$17.52

The accompanying Notes to the Consolidated Financial Statements (unaudited) are an integral part of these statements.

The Cigna Group Consolidated Statements of Comprehensive Income
UnauditedUnaudited
Three Months Ended September 30,Nine Months Ended September 30,
(In millions)2026202520262025
Net income$1,698$1,973$5,434$5,014
Other comprehensive income (loss), net of tax
Net unrealized appreciation (depreciation) on securities and derivatives11(401)131(180)
Net long-duration insurance and contractholder liabilities measurement adjustments(105)421(1,752)(356)
Net translation (losses) gains on foreign currencies(23)(10)(71)68
Postretirement benefits liability adjustment672610
Other comprehensive (loss) income, net of tax(111)17(1,666)(458)
Total comprehensive income1,5871,9903,7684,556
Less: Net income attributable to noncontrolling interests256105678291
SHAREHOLDERS' COMPREHENSIVE INCOME$1,331$1,885$3,090$4,265

The accompanying Notes to the Consolidated Financial Statements (unaudited) are an integral part of these statements.

The Cigna Group Consolidated Balance Sheets
Unaudited
As of September 30,As of December 31,
(In millions)20262025
Assets
Cash and cash equivalents$6,186$7,676
Investments1,1091,056
Accounts receivable, net31,49228,768
Inventories5,5557,338
Other current assets2,8902,976
Total current assets47,23247,814
Long-term investments19,04318,471
Reinsurance recoverables3,7294,103
Property and equipment3,7393,651
Goodwill45,53744,924
Other intangible assets26,75528,560
Other assets4,3012,885
Separate account assets7,3087,511
TOTAL ASSETS$157,644$157,919
Liabilities
Current insurance and contractholder liabilities$6,404$5,710
Pharmacy and other service costs payable27,36830,333
Accounts payable10,10010,659
Accrued expenses and other liabilities9,8689,048
Short-term debt2,293592
Total current liabilities56,03356,342
Non-current insurance and contractholder liabilities9,2429,938
Deferred tax liabilities, net6,5737,145
Other non-current liabilities5,9174,238
Long-term debt28,84930,871
Separate account liabilities7,3087,511
TOTAL LIABILITIES113,922116,045
Contingencies — Note 14
Shareholders' equity
Common stock (1)44
Additional paid-in capital32,18931,790
Accumulated other comprehensive loss(4,472)(2,806)
Retained earnings51,38547,865
Less: Treasury stock, at cost(35,723)(35,140)
TOTAL SHAREHOLDERS' EQUITY43,38341,713
Noncontrolling interests339161
Total equity43,72241,874
Total liabilities and equity$157,644$157,919

*(1)*Par value per share, $0.01; shares issued, 407 million as of September 30, 2026 and 405 million as of December 31, 2025; authorized shares, 600 million.

The accompanying Notes to the Consolidated Financial Statements (unaudited) are an integral part of these statements.

The Cigna Group
Consolidated Statements of Changes in Total Equity
Unaudited
Three Months Ended September 30, 2026
(In millions)Common StockAdditional Paid-in CapitalAccumulated Other Comprehensive (Loss)Retained EarningsTreasury StockShareholders' EquityNoncontrolling InterestsTotal Equity
Balance at June 30, 2026$4$32,092$(4,361)$50,355$(35,470)$42,620$290$42,910
Effect of issuing stock for employee benefit plans97(1)9696
Other comprehensive loss(111)(111)(111)
Net income1,4421,4422561,698
Common dividends declared (per share: $1.56)(412)(412)(412)
Repurchase of common stock—(252)(252)(252)
Other transactions impacting noncontrolling interests——(207)(207)
Balance at September 30, 2026$4$32,189$(4,472)$51,385$(35,723)$43,383$339$43,722
Three Months Ended September 30, 2025
(In millions)Common StockAdditional Paid-in CapitalAccumulated Other Comprehensive (Loss)Retained EarningsTreasury StockShareholders' EquityNoncontrolling InterestsTotal Equity
Balance at June 30, 2025$4$31,588$(2,816)$45,564$(34,126)$40,214$216$40,430
Effect of issuing stock for employee benefit plans110(3)107107
Other comprehensive income171717
Net income1,8681,8681051,973
Common dividends declared (per share: $1.51)(404)(404)(404)
Repurchase of common stock—333
Other transactions impacting noncontrolling interests——(112)(112)
Balance at September 30, 2025$4$31,698$(2,799)$47,028$(34,126)$41,805$209$42,014

The accompanying Notes to the Consolidated Financial Statements (unaudited) are an integral part of these statements.

The Cigna Group
Consolidated Statements of Changes in Total Equity
Unaudited
Nine Months Ended September 30, 2026
(In millions)Common StockAdditional Paid-in CapitalAccumulated Other Comprehensive (Loss)Retained EarningsTreasury StockShareholders' EquityNoncontrolling InterestsTotal Equity
Balance at December 31, 2025$4$31,790$(2,806)$47,865$(35,140)$41,713$161$41,874
Effect of issuing stock for employee benefit plans402(81)321321
Other comprehensive loss(1,666)(1,666)(1,666)
Net income4,7564,7566785,434
Common dividends declared (per share: $4.68)(1,236)(1,236)(1,236)
Repurchase of common stock—(502)(502)(502)
Other transactions impacting noncontrolling interests(3)(3)(500)(503)
Balance at September 30, 2026$4$32,189$(4,472)$51,385$(35,723)$43,383$339$43,722
Nine Months Ended September 30, 2025
(In millions)Common StockAdditional Paid-in CapitalAccumulated Other Comprehensive (Loss)Retained EarningsTreasury StockShareholders' EquityNoncontrolling InterestsTotal Equity
Balance at December 31, 2024$4$31,288$(2,341)$43,519$(31,437)$41,033$210$41,243
Effect of issuing stock for employee benefit plans410(111)299299
Other comprehensive loss(458)(458)(458)
Net income4,7234,7232915,014
Common dividends declared (per share: $4.53)(1,214)(1,214)(1,214)
Repurchase of common stock—(2,578)(2,578)(2,578)
Other transactions impacting noncontrolling interests——(292)(292)
Balance at September 30, 2025$4$31,698$(2,799)$47,028$(34,126)$41,805$209$42,014

The accompanying Notes to the Consolidated Financial Statements (unaudited) are an integral part of these statements.

The Cigna Group

Consolidated Statements of Cash Flows

Unaudited
Nine Months Ended September 30,
(In millions)20262025
Cash Flows from Operating Activities
Net income$5,434$5,014
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization2,1722,053
Investment gains, net(225)(76)
Deferred income tax benefit(266)(174)
Gain on sale of businesses(17)(79)
Net changes in assets and liabilities, net of non-operating effects:
Accounts receivable, net(2,770)(6,911)
Inventories1,7821,060
Reinsurance recoverable and Other assets25(537)
Insurance liabilities4891,662
Pharmacy and other service costs payable(2,964)1,837
Accounts payable and Accrued expenses and other liabilities(104)(857)
Other, net(275)460
NET CASH PROVIDED BY OPERATING ACTIVITIES3,2813,452
Cash Flows from Investing Activities
Proceeds from investments sold:
Debt securities and equity securities156518
Investment maturities and repayments:
Debt securities and equity securities595745
Commercial mortgage loans132198
Other sales, maturities and repayments (primarily short-term and other long-term investments)717656
Investments purchased or originated:
Debt securities and equity securities(1,248)(5,271)
Commercial mortgage loans(101)(117)
Other (primarily short-term and other long-term investments)(1,101)(1,066)
Property and equipment purchases, net(842)(890)
Acquisitions, net of cash acquired—(597)
Divestitures, net of cash sold262,346
Renewable energy tax credit equity investments(312)(485)
Other, net(436)(24)
NET CASH USED IN INVESTING ACTIVITIES(2,414)(3,987)
Cash Flows from Financing Activities
Deposits and interest credited to contractholder deposit funds104113
Withdrawals and benefit payments from contractholder deposit funds(248)(201)
Net change in short-term debt, excluding term loan463(915)
Net proceeds on issuance of term loan—1,999
Repayment of term loan—(2,000)
Repayment of long-term debt(590)(1,643)
Net proceeds on issuance of long-term debt—4,461
Repurchase of common stock(531)(2,620)
Issuance of common stock191178
Common stock dividend paid(1,236)(1,215)
Other, net(529)(512)
NET CASH USED IN FINANCING ACTIVITIES(2,376)(2,355)
Effect of foreign currency rate changes on cash, cash equivalents and restricted cash(15)30
Net decrease in cash, cash equivalents and restricted cash(1,524)(2,860)
Cash, cash equivalents and restricted cash January 1, (1)7,7368,931
Cash, cash equivalents and restricted cash September 30, (1)$6,212$6,071

*(1)*Restricted cash and cash equivalents were reported in other long-term investments and Other assets.

The accompanying Notes to the Consolidated Financial Statements (unaudited) are an integral part of these statements.

THE CIGNA GROUP

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

TABLE OF CONTENTS

Note NumberFootnotePage
B****USINESS AND C****APITAL S****TRUCTURE
1Description of Business10
2Summary of Significant Accounting Policies10
3Accounts Receivable, Net11
4Supplier Finance Program12
5Earnings Per Share12
6Debt13
I****NSURANCE I****NFORMATION
7Insurance and Contractholder Liabilities13
8Reinsurance16
I****NVESTMENTS
9Investments17
10Fair Value Measurements19
11Accumulated Other Comprehensive Income (Loss)22
W****ORKFORCE M****ANAGEMENT AND C****OMPENSATION
12Strategic Optimization Program23
COMPLIANCE, R****EGULATION AND C****ONTINGENCIES
13Income Taxes24
14Contingencies and Other Matters24
R****ESULTS D****ETAILS
15Segment Information25

Note 1 – Description of Business

The Cigna Group®, together with its subsidiaries (either individually or collectively referred to as the "Company," "we," "us" or "our"), is a global health company committed to creating a better future for every individual and every community. Powered by our dedicated people and valued brands, we advance our mission to improve the health and vitality of those we serve.

Our subsidiaries offer a differentiated set of pharmacy, medical, behavioral, dental, and related products and services. The majority of these products and services are offered through employers and other entities, such as governmental and nongovernmental organizations, unions and associations. Certain subsidiaries also offer health and dental insurance products to individuals in the United States and select international markets. In addition to these operations, The Cigna Group also has certain run-off operations.

A full description of our segments follows:

The Evernorth Health Services® reportable segment includes the Pharmacy Benefit Services and the Specialty and Care Services operating segments, which provide independent and coordinated health solutions and capabilities to enable the health care system to work better and help people live healthier lives.

Pharmacy Benefit Services drives high-quality, cost-effective pharmacy care through various services, such as drug claim adjudication, retail pharmacy network administration, benefit design consultation, drug utilization review, drug formulary management and access to our home delivery pharmacy. Specialty and Care Services provides specialty drugs for the treatment of complex and rare diseases, specialty distribution of pharmaceuticals and medical supplies, as well as clinical programs to help our clients drive better whole-person health outcomes through care services.

The Cigna Healthcare**®** reportable segment includes the U.S. Healthcare and International Health operating segments, which provide comprehensive medical and coordinated solutions to clients and customers. U.S. Healthcare provides medical plans and other benefits and solutions for insured and self-insured clients as well as for individual and family plan customers. International Health provides health care solutions in our international markets, as well as health solutions for globally mobile individuals and employees of multinational organizations. U.S. Healthcare also included the Medicare Advantage and related businesses until the divestiture of such businesses to Health Care Services Corporation ("HCSC") on March 19, 2025 ("HCSC transaction"). In April 2026, the Company announced its planned exit from the Individual and Family Plans medical business as of January 1, 2027.

Other Operations comprises the remainder of our business operations, which includes certain continuing business (corporate-owned life insurance ("COLI")), as well as run-off and other non-strategic businesses. Our run-off businesses include the (i) variable annuity reinsurance business that was effectively exited through reinsurance with Berkshire Hathaway Life Insurance Company of Nebraska ("Berkshire") in 2013; (ii) settlement annuity business; and (iii) individual life insurance and annuity and retirement benefits businesses, which were sold through reinsurance agreements.

Corporate reflects amounts not allocated to operating segments, including net interest expense (defined as interest on corporate financing less net investment income on investments not supporting segment and other operations), certain litigation matters, expense associated with our frozen pension plans, charitable contributions, operating severance, certain overhead and enterprise-wide project costs, and eliminations for products and services sold between segments.

Note 2 – Summary of Significant Accounting Policies

Basis of Presentation

The Consolidated Financial Statements include the accounts of The Cigna Group and its consolidated subsidiaries. Intercompany transactions and accounts have been eliminated in consolidation. These Consolidated Financial Statements were prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP"). Certain goodwill and other intangible assets amounts in the Consolidated Balance Sheet were reclassified in the first quarter of 2026. Amounts as of September 30, 2026 continue to reflect the reclassified presentation.

Amounts recorded in the Consolidated Financial Statements necessarily reflect management's estimates and assumptions about medical costs, investment, tax and receivable valuations, interest rates, and other factors. Significant estimates are discussed throughout these Notes; however, actual results could differ from those estimates. The impact of a change in estimate is generally included in earnings in the period of adjustment.

These interim Consolidated Financial Statements are unaudited but include all adjustments (including normal recurring adjustments) necessary, in the opinion of management, for a fair statement of financial position and results of operations for the periods reported. The interim Consolidated Financial Statements and Notes should be read in conjunction with the Consolidated Financial Statements

and Notes included in the Company's Annual Report on Form 10-K for the year ended December 31, 2025 ("2025 Form 10-K"). The Company has not included certain footnote disclosures that would substantially duplicate the disclosures contained in its 2025 Form 10-K, unless the information in those disclosures materially changed or is required by GAAP. The preparation of interim Consolidated Financial Statements necessarily relies heavily on estimates. This and other factors, including the seasonal nature of portions of the health care and related benefits business, as well as competitive and other market conditions, call for caution in estimating full-year results based on interim results of operations.

Recent Accounting Pronouncements

The Company's 2025 Form 10-K includes discussion of significant recent accounting pronouncements that either have impacted or may impact our financial statements in the future. There are no updates to significant accounting pronouncements recently adopted that have occurred since the Company filed its 2025 Form 10-K. There are no incremental significant accounting pronouncements recently issued and not yet adopted that are expected to impact our operations or financial statements beyond those described in the Company's 2025 Form 10-K*.* The Company continues to progress with its adoption plans, with no significant updates since the 2025 Form 10-K.

Note 3 – Accounts Receivable, Net

The following amounts were included within Accounts receivable, net:

(In millions)September 30, 2026December 31, 2025
Noninsurance customer receivables$15,646$14,707
Pharmaceutical manufacturers receivables14,11012,437
Insurance customer receivables1,5101,385
Other receivables226239
Total$31,492$28,768

These accounts receivable are reported net of our allowances of $8.0 billion and $6.8 billion as of September 30, 2026 and December 31, 2025, respectively. These allowances include contractual allowances for certain rebates receivable with pharmaceutical manufacturers and certain accounts receivable from third-party payors, discounts and claims adjustments issued to customers in the form of client credits, an allowance for current expected credit losses, and other non-credit adjustments.

The Company's allowance for current expected credit losses was $240 million and $199 million as of September 30, 2026 and December 31, 2025, respectively.

Accounts Receivable Factoring Facilities

The Company maintains uncommitted factoring facilities with a total capacity of $2.0 billion under which certain accounts receivable may be sold on a non-recourse basis to a financial institution. In the first quarter of 2026, the Company entered into a new accounts receivable factoring facility with an initial two-year term, in addition to the previously established accounts receivable factoring facility outlined in Note 3 to the Consolidated Financial Statements included in the Company's 2025 Form 10-K (together, the "Facilities"). The Facilities are subject to automatic one-year renewal terms following the expiration of the initial term unless terminated by either party. The transactions under the Facilities are accounted for as a sale and recorded as a reduction to accounts receivable in the Consolidated Balance Sheets because control of, and risk related to, the accounts receivable are transferred to the financial institution. Although the sale is made without recourse, we provide collection services related to the transferred assets. Amounts associated with the Facilities are reflected within Net cash provided by operating activities in the Consolidated Statements of Cash Flows. Factoring fees paid under the Facilities are reflected in Interest expense and other in the Consolidated Statements of Income.

We sold accounts receivable under the Facilities of $0.5 billion and $1.3 billion for the three months ended September 30, 2026 and 2025, respectively, and $2.0 billion and $4.0 billion for the nine months ended September 30, 2026 and 2025, respectively. For the three and nine months ended September 30, 2026 and 2025, factoring fees paid were not material. As of September 30, 2026, there were $0.3 billion of sold accounts receivable that have not been collected and have been removed from the Company's Consolidated Balance Sheets. As of December 31, 2025, all sold accounts receivable had been collected. As of September 30, 2026 and December 31, 2025, there were $0.2 billion and $0.4 billion, respectively, of collections that had not been remitted to the financial institution. Such amounts are recorded within Accrued expenses and other liabilities in the Consolidated Balance Sheets.

Note 4 – Supplier Finance Program

The Company facilitates a voluntary supplier finance program (the "Program") that provides suppliers the opportunity to sell their accounts receivable due from us (i.e., our payment obligations to the suppliers) to a financial institution, on a non-recourse basis, in order to be paid earlier than our payment terms require.

As of September 30, 2026 and December 31, 2025, $1.4 billion and $1.6 billion, respectively, of the Company's outstanding payment obligations were confirmed as valid within the Program by the financial institution and are reflected in Accounts payable in the Consolidated Balance Sheets. The amounts confirmed as valid for both periods are predominantly associated with one supplier.

Note 5 – Earnings Per Share

Basic and diluted earnings per share were computed as follows:

Three Months Ended
September 30, 2026September 30, 2025
(Shares in thousands, dollars in millions, except per share amounts)BasicEffect of DilutionDilutedBasicEffect of DilutionDiluted
Shareholders' net income$1,442$1,442$1,868$1,868
Shares:
Weighted average262,790262,790265,913265,913
Common stock equivalents9989981,6171,617
Total shares262,790998263,788265,9131,617267,530
Earnings per share$5.49$(0.02)$5.47$7.02$(0.04)$6.98
Nine Months Ended
September 30, 2026September 30, 2025
(Shares in thousands, dollars in millions, except per share amounts)BasicEffect of DilutionDilutedBasicEffect of DilutionDiluted
Shareholders' net income$4,756$4,756$4,723$4,723
Shares:
Weighted average262,841262,841267,635267,635
Common stock equivalents1,0821,0821,8921,892
Total shares262,8411,082263,923267,6351,892269,527
Earnings per share$18.09$(0.07)$18.02$17.65$(0.13)$17.52

The following outstanding employee stock options were not included in the computation of diluted earnings per share because their effect was anti-dilutive:

Three Months Ended September 30,Nine Months Ended September 30,
(In millions)2026202520262025
Anti-dilutive options2.12.12.21.9

On October 28, 2026, the Board of Directors of The Cigna Group (the "Board") declared the fourth quarter cash dividend of $1.56 per share of The Cigna Group common stock to be paid on December 17, 2026 to shareholders of record on December 3, 2026. The Company currently intends to pay regular quarterly dividends, with future declarations subject to approval by the Board and the Board's determination that the declaration of dividends remains in the best interests of The Cigna Group and its shareholders. The decision of whether to pay future dividends and the amount of any such dividends will be based on the Company's financial position, results of operations, cash flows, capital requirements, the requirements of applicable law and any other factors the Board may deem relevant.

The Company held approximately 143.2 million shares of common stock in treasury as of September 30, 2026, 141.1 million shares as of December 31, 2025 and 137.4 million shares as of September 30, 2025.

Note 6 – Debt

Short-Term and Long-Term Debt. During the nine months ended September 30, 2026, the Company repaid $550 million 1.250% senior notes that matured in March 2026. For more information regarding our short-term and long-term debt, see Note 7 to the Consolidated Financial Statements in the Company's 2025 Form 10-K.

Revolving Credit Agreement. The Company maintains a $6.5 billion, five-year revolving credit and letter of credit agreement that will mature in April 2030, with an option to extend the maturity date for additional one-year periods, subject to consent of the banks (the "Credit Agreement"). Our Credit Agreement provides us with the ability to borrow amounts for general corporate purposes, including providing liquidity support if necessary under our commercial paper program discussed below. As of September 30, 2026, there was no outstanding balance under the Credit Agreement.

Commercial Paper. Under our commercial paper program, we may issue short-term, unsecured commercial paper notes privately placed on a discounted basis through certain broker-dealers at any time not to exceed an aggregate amount of $6.5 billion. Amounts available under the program may be borrowed, repaid and re-borrowed from time to time. The net proceeds of issuances have been and are expected to be used for general corporate purposes. The commercial paper program had approximately $0.5 billion outstanding as of September 30, 2026 and an average interest rate of 4.09%.

Interest Expense. Interest expense on long-term and short-term debt was $356 million for the three months ended and $1.1 billion for the nine months ended September 30, 2026, compared with $363 million for the three months ended and $1.1 billion for the nine months ended September 30, 2025.

Note 7 – Insurance and Contractholder Liabilities

**A.**Account Balances – Insurance and Contractholder Liabilities

The Company's insurance and contractholder liabilities were comprised of the following:

September 30, 2026December 31, 2025September 30, 2025
(In millions)CurrentNon-currentTotalCurrentNon-currentTotalTotal
Unpaid claims and claim expenses
Cigna Healthcare$4,923$65$4,988$4,180$61$4,241$4,676
Other152143295167176343335
Future policy benefits
Cigna Healthcare3815219038153191192
Other Operations1422,7992,9411423,0813,2233,297
Contractholder deposit funds3125,5725,8843365,7786,1146,132
Market risk benefits2246849025649674709
Unearned premiums8154385882240862756
Total insurance and contractholder liabilities$6,404$9,242$15,646$5,710$9,938$15,648$16,097

Insurance and contractholder liabilities expected to be paid within one year are classified as current.

**B.**Unpaid Claims and Claim Expenses – Cigna Healthcare

This liability reflects estimates of the ultimate cost of claims that have been incurred but not reported, expected development on reported claims, claims that have been reported but not yet paid (reported claims in process), and other medical care expenses and services payable that are primarily comprised of accruals for incentives and other amounts payable to health care professionals and facilities.

The total of incurred but not reported liabilities plus expected development on reported claims and reported claims in process was $4.8 billion as of September 30, 2026 and $4.5 billion as of September 30, 2025.

Activity, net of intercompany transactions, in the unpaid claims liability for the Cigna Healthcare segment was as follows:

Nine Months Ended September 30,
(In millions)20262025 (1)
Beginning balance$4,241$5,018
Less: Reinsurance and other amounts recoverable147159
Beginning balance, net4,0944,859
Incurred costs related to:
Current year24,40925,763
Prior years(356)(319)
Total incurred24,05325,444
Paid costs related to:
Current year19,88020,399
Prior years3,4124,055
Total paid23,29224,454
Less: Divestiture and other—1,323
Ending balance, net4,8554,526
Add: Reinsurance and other amounts recoverable133150
Ending balance$4,988$4,676

(1) Includes unpaid claims amounts classified as liabilities of businesses held for sale prior to the completion of the HCSC transaction. As of December 31, 2024, includes $983 million classified as liabilities of businesses held for sale.

Reinsurance and other amounts recoverable reflect amounts due from reinsurers and policyholders to cover incurred but not reported and pending claims of certain business for which the Company administers the plan benefits without any right of offset. See Note 8 to the Consolidated Financial Statements for additional information on reinsurance.

Variances in incurred costs related to prior years' unpaid claims and claim expenses that resulted from the differences between actual experience and the Company's key assumptions were as follows:

Nine Months Ended September 30,
20262025
(Dollars in millions)$% (1)$% (2)
Actual completion factors and other$2100.7%$1850.5%
Medical cost trend1460.41340.3
Total favorable variance$3561.1%$3190.8%

*(1)*Percentage of current year incurred costs as reported for the year ended December 31, 2025.

*(2)*Percentage of current year incurred costs as reported for the year ended December 31, 2024.

Favorable prior year development in both years primarily reflects lower than expected utilization of medical services as compared to our assumptions.

**C.**Future Policy Benefits

The weighted average interest rates applied and duration for future policy benefits in Other Operations, consisting of annuity and life insurance products, were as follows:

As of
September 30, 2026September 30, 2025
Interest accretion rate5.64%5.64%
Current discount rate6.15%5.11%
Weighted average duration10.0 years10.8 years

Obligations for annuities represent discounted periodic benefits to be paid to an individual or groups of individuals over their remaining lives. Other Operations' traditional insurance contracts, which are in run-off, have no premium remaining to be collected; therefore, future policy benefit reserves represent the present value of expected future policy benefits, discounted using the current discount rate, and the remaining amortizable deferred profit liability.

Future policy benefits include deferred profit liability of $0.3 billion as of September 30, 2026 and $0.4 billion as of September 30, 2025. Future policy benefits excluding deferred profit liability were $2.6 billion as of September 30, 2026 and $2.9 billion as of December 31, 2025, September 30, 2025, and December 31, 2024. Undiscounted expected future policy benefits were $4.1 billion as of September 30, 2026 and $4.2 billion as of September 30, 2025. As of September 30, 2026 and September 30, 2025, $0.8 billion and $0.9 billion, respectively, of the future policy benefit reserve was recoverable through treaties with external reinsurers.

**D.**Contractholder Deposit Funds

Contractholder deposit fund liabilities within Other Operations were $5.9 billion as of September 30, 2026, $6.1 billion as of both December 31, 2025 and September 30, 2025, and $6.3 billion as of December 31, 2024. Approximately 37% of the balance is reinsured externally. Activity in these liabilities is presented net of reinsurance in the Consolidated Statements of Cash Flows.

As of September 30, 2026, the weighted average crediting rate, net amount at risk and cash surrender value for contractholder deposit fund liabilities not effectively exited through reinsurance were 3.21%, $2.3 billion and $2.7 billion, respectively. The comparative amounts as of September 30, 2025 were 3.26%, $2.6 billion and $2.8 billion, respectively. More than 99% of the $3.7 billion liability as of September 30, 2026 and the $3.9 billion liability as of September 30, 2025 not reinsured externally is for contracts with guaranteed interest rates of 3% - 4%, and approximately $1.1 billion and $1.2 billion as of these period ends represented contracts with policies at the guarantee. At these same period ends, $1.0 billion and $1.1 billion was 50 - 150 basis points ("bps") above the guarantee, and the remaining $1.6 billion as of both September 30, 2026 and September 30, 2025 represented contracts above the guarantee that pay the policyholder based on the greater of a guaranteed minimum cash value or the actual cash value. As of both September 30, 2026 and September 30, 2025, more than 90% of these contracts have actual cash values of at least 110% of the guaranteed cash value.

**E.**Market Risk Benefits

Liabilities for market risk benefits ("MRBs") consist of variable annuity reinsurance contracts in Other Operations. These liabilities arise under annuities and riders to annuities written by ceding companies that guarantee the benefit received at death and, for a subset of policies, also provide contractholders the option, within 30 days of a policy anniversary after the appropriate waiting period, to elect minimum income payments. The Company's capital market risk exposure on variable annuity reinsurance contracts arises when the reinsured guaranteed minimum benefit exceeds the contractholder's account value in the related underlying mutual funds at the time the insurance benefit is payable under the respective contract. The Company receives and pays premium periodically based on the terms of the reinsurance agreements.

Market risk benefits activity was as follows:

Nine Months Ended September 30,
(In millions)20262025
Balance, beginning of year$674$785
Balance, beginning of year, before the effect of nonperformance risk (own credit risk)714838
Changes due to expected run-off(15)(14)
Changes due to capital markets versus expected(160)(30)
Changes due to policyholder behavior versus expected(14)(20)
Assumption changes(11)(17)
Balance, end of period, before the effect of changes in nonperformance risk (own credit risk)514757
Nonperformance risk (own credit risk), end of period(24)(48)
Balance, end of period$490$709
Reinsured market risk benefit, end of period$514$756

The following table presents the net amount at risk and the average attained age of contractholders (weighted by exposure) for contracts assumed by the Company. The net amount at risk is the amount the Company would have to pay to contractholders if all deaths or annuitizations occurred as of the earliest possible date in accordance with the insurance contract. The Company should be reimbursed in full for these payments unless the Berkshire reinsurance limit is exceeded, as discussed further in Note 8 to the Consolidated Financial Statements.

(Dollars in millions, excludes impact of reinsurance ceded)September 30, 2026September 30, 2025
Net amount at risk$989$1,141
Average attained age of contractholders (weighted by exposure)78.5 years78.2 years

Note 8 – Reinsurance

The Company's insurance subsidiaries enter into agreements with other insurance companies to limit losses from large exposures and to permit recovery of a portion of incurred losses. Reinsurance is ceded primarily in acquisition and disposition transactions when the underwriting company is not being acquired. Reinsurance does not relieve the originating insurer of liability. Therefore, reinsured liabilities must continue to be reported along with the related reinsurance recoverables. The Company regularly evaluates the financial condition of its reinsurers and monitors concentrations of its credit risk.

The majority of the Company's reinsurance recoverables resulted from acquisition and disposition transactions in which the underwriting company was not acquired. The Company bears the risk of loss if its reinsurers and retrocessionaires do not meet or are unable to meet their reinsurance obligations to the Company. The Company reviews its reinsurance arrangements and establishes reserves against the recoverables primarily for expected credit losses.

The Company's reinsurance recoverables as of September 30, 2026 are presented at amount due by range of external credit rating and collateral level in the following table, with reinsurance recoverables that are market risk benefits separately presented at fair value:

(In millions)Fair Value of Collateral Contractually Required to Meet or Exceed Carrying Value of RecoverableCollateral Provisions Exist That May Mitigate Risk of Credit Loss (1)No CollateralTotal
Ongoing operations
A- equivalent and higher current ratings (2)$—$4$203$207
BBB- to BBB+ equivalent current credit ratings (2)——6464
Not rated768690
Acquisition, disposition or run-off activities
BBB+ equivalent and higher current ratings (2)(3)2602,711162,987
Not rated—5—5
Total reinsurance recoverables before market risk benefits$336$2,728$289$3,353
Allowance for uncollectible reinsurance(22)
Market risk benefits514
Total reinsurance recoverables (4)$3,845

*(1)*Includes collateral provisions requiring the reinsurer to fully collateralize its obligation if its external credit rating is downgraded to a specified level.

*(2)*Certified by a nationally recognized statistical ratings organization ("NRSRO").

*(3)*Comprised of six reinsurers, of which 78% is held by two reinsurers, Lincoln National Life Insurance Company and Lincoln Life and Annuity Company of New York.

*(4)*Includes $116 million of current reinsurance recoverables that are reported in Other current assets.

The Company entered into an agreement with Berkshire to effectively exit the variable annuity reinsurance business via a reinsurance transaction in 2013. Variable annuity contracts are accounted for as assumed and ceded reinsurance and categorized as market risk benefits as discussed in Note 7 to the Consolidated Financial Statements. Berkshire reinsured 100% of the Company's future cash flows in this business, net of other reinsurance arrangements existing at that time. The reinsurance agreement is subject to an overall limit, with approximately $3.0 billion remaining as of September 30, 2026. As a result of the reinsurance transaction, amounts payable are offset by a corresponding reinsurance recoverable, provided the increased recoverable remains within the overall Berkshire limit. As of both September 30, 2026 and 2025, market risk benefits (shown in the table net of nonperformance risk as of September 30, 2026) were predominantly reinsured by Berkshire, which is rated AA+ by an NRSRO. As of September 30, 2026, approximately 100% of the Berkshire recoverable is secured by assets in a trust.

Note 9 – Investments

The following table summarizes the Company's investments by category and current or long-term classification:

September 30, 2026December 31, 2025
(In millions)CurrentLong-TermTotalCurrentLong-TermTotal
Debt securities$689$7,712$8,401$691$7,671$8,362
Equity securities233,8043,827223,5343,556
Commercial mortgage loans671,1351,202861,1471,233
Policy loans—966966—1,0821,082
Other long-term investments—5,4265,426—5,0375,037
Short-term investments330—330257—257
Total$1,109$19,043$20,152$1,056$18,471$19,527

**A.**Investment Portfolio

Debt Securities

The amortized cost and fair value by contractual maturity periods for debt securities were as follows as of September 30, 2026:

(In millions)Amortized CostFair Value
Due in one year or less$740$715
Due after one year through five years3,9883,832
Due after five years through ten years2,2242,100
Due after ten years1,8361,543
Mortgage and other asset-backed securities240211
Total$9,028$8,401

Actual maturities of these securities could differ from their contractual maturities used in the table above because issuers may have the right to call or prepay obligations, with or without penalties.

Gross unrealized appreciation (depreciation) on debt securities by type of issuer is shown below:

(In millions)Amortized CostAllowance for Credit LossUnrealized AppreciationUnrealized DepreciationFair Value
September 30, 2026
Federal government and agency$218$—$8$(7)$219
State and local government24——(1)23
Foreign government441—2(12)431
Corporate8,105(51)49(586)7,517
Mortgage and other asset-backed240——(29)211
Total$9,028$(51)$59$(635)$8,401
December 31, 2025
Federal government and agency$215$—$15$(3)$227
State and local government24—1—25
Foreign government450—12(6)456
Corporate7,704(137)175(332)7,410
Mortgage and other asset-backed267—3(26)244
Total$8,660$(137)$206$(367)$8,362

Review of Declines in Fair Value. Management reviews debt securities in an unrealized loss position to determine whether a credit loss allowance is needed based on criteria that include severity of decline; financial health and specific prospects of the issuer; and changes in the regulatory, economic or general market environment of the issuer's industry or geographic region.

The table below summarizes debt securities with a decline in fair value from amortized cost for which an allowance for credit losses has not been recorded (by investment grade and the length of time these securities have been in an unrealized loss position). Unrealized depreciation on these debt securities is primarily due to declines in fair value resulting from increasing interest rates since these securities were purchased.

September 30, 2026December 31, 2025
(Dollars in millions)Fair ValueAmortized CostUnrealized DepreciationNumber of IssuesFair ValueAmortized CostUnrealized DepreciationNumber of Issues
One year or less
Investment grade$3,786$3,923$(137)1,253$384$386$(2)149
Below investment grade348360(12)834120125(5)239
More than one year
Investment grade2,4402,910(470)6733,0443,382(338)799
Below investment grade135151(16)84185207(22)86
Total$6,709$7,344$(635)2,844$3,733$4,100$(367)1,273

Equity Securities

The following table provides the values of the Company's equity security investments:

September 30, 2026December 31, 2025
(In millions)CostCarrying ValueCostCarrying Value
Equity securities with readily determinable fair values$96$106$78$92
Equity securities with no readily determinable fair value7,0783,7216,7923,464
Total$7,174$3,827$6,870$3,556

Commercial Mortgage Loans

Mortgage loans held by the Company are made exclusively to commercial borrowers and are diversified by property type, location and borrower. Loans are generally issued at fixed rates of interest and are secured by high-quality, primarily completed and substantially leased operating properties.

The Company regularly evaluates and monitors credit risk from the initial mortgage loan underwriting and throughout the investment holding period. The annual portfolio review performed in the second quarter of 2026 confirmed ongoing strong overall credit quality in line with the previous year's results. For more information on the Company's accounting policies and methodologies regarding these investments, see Note 11 to the Consolidated Financial Statements in the Company's 2025 Form 10-K.

The following table summarizes the credit risk profile of the Company's commercial mortgage loan portfolio:

(Dollars in millions)September 30, 2026December 31, 2025
Loan-to-Value RatioCarrying ValueAverage Debt Service Coverage RatioAverage Loan-to-Value RatioCarrying ValueAverage Debt Service Coverage RatioAverage Loan-to-Value Ratio
Below 60%$2742.35$3552.13
60% to 79%7421.636941.81
80% to 100%1860.961840.79
Total$1,2021.6772%$1,2331.7271%

Other Long-Term Investments

Other long-term investments include investments in unconsolidated entities, including certain limited partnerships and limited liability companies holding real estate, securities or loans. These investments are carried at cost plus the Company's ownership percentage of reporting income or loss, based on the financial statements of the underlying investments that are generally reported at fair value.

Income or loss from these investments is reported on a one-quarter lag due to the timing of when financial information is received from the general partner or manager of the investments.

Other long-term investments also include investment real estate carried at depreciated cost less any impairment write-downs to fair value when cash flow estimates indicate that the carrying value may not be recoverable. Additionally, statutory and other restricted deposits and foreign currency swaps carried at fair value are reported in the table below as Other. The following table provides the carrying value information for these investments:

Carrying Value as of
(In millions)September 30, 2026December 31, 2025
Real estate investments$2,054$1,895
Securities partnerships3,1762,948
Other196194
Total$5,426$5,037

**B.**Derivative Financial Instruments

The Company uses derivative financial instruments to manage the characteristics of investment assets (such as duration, yield, currency and liquidity) to meet the varying demands of the related insurance and contractholder liabilities. The Company also uses derivative financial instruments to hedge the risk of changes in the net assets of certain of its foreign subsidiaries due to changes in foreign currency exchange rates and to hedge the interest rate risk of certain long-term debt. The Company also has derivative instruments associated with certain equity securities; see Note 12A to the Consolidated Financial Statements in the Company’s 2025 Form 10-K for further information.

As of September 30, 2026, the notional value of interest rate swap contracts increased to $4.1 billion compared with $3.2 billion as of December 31, 2025. There were no other material changes to the Company's individual derivative hedging strategies during the three and nine months ended September 30, 2026. See Note 11B to the Consolidated Financial Statements in the Company's 2025 Form 10-K for further discussion of the types of derivative financial instruments and associated accounting policies. The effects of derivative financial instruments used in our individual hedging strategies were not material to the Consolidated Financial Statements as of September 30, 2026 and December 31, 2025. The gross fair values of our derivative financial instruments are presented in Note 10 to the Consolidated Financial Statements.

**C.**Investment Gains and Losses

Net investment gains (losses), before income taxes were $36 million and $225 million, respectively, for the three and nine months ended September 30, 2026, versus $26 million and $76 million, respectively, for the three and nine months ended September 30, 2025. Net investment results for the three and nine months ended September 30, 2026 primarily reflect fair value changes of derivative instruments associated with certain equity securities. These amounts exclude investment gains and losses attributed to the Company's separate accounts because those gains and losses generally accrue directly to separate account policyholders.

Note 10 – Fair Value Measurements

For a description of the policies, methods and assumptions that are used to estimate fair value and determine the fair value hierarchy for each class of financial instruments, see Note 12 to the Consolidated Financial Statements in the Company's 2025 Form 10-K.

**A.**Financial Assets and Financial Liabilities Carried at Fair Value

The following table provides information about the Company's investment and derivative financial assets and liabilities carried at fair value on a recurring basis. Further information regarding insurance assets and liabilities carried at fair value is provided in Note 9E to the Consolidated Financial Statements in the Company's 2025 Form 10-K. Separate account assets are also recorded at fair value on the Company's Consolidated Balance Sheets and are reported separately in the Separate Accounts section below as gains and losses related to these assets generally accrue directly to contractholders.

(In millions)Quoted Prices in Active Markets for Identical Assets (Level 1)Significant Other Observable Inputs (Level 2)Significant Unobservable Inputs (Level 3)Total
September 30, 2026December 31, 2025September 30, 2026December 31, 2025September 30, 2026December 31, 2025September 30, 2026December 31, 2025
Financial assets at fair value
Debt securities
Federal government and agency$102$105$117$122$—$—$219$227
State and local government——2325——2325
Foreign government——431446—10431456
Corporate——7,2757,1332422777,5177,410
Mortgage and other asset-backed——1802063138211244
Total debt securities1021058,0267,9322733258,4018,362
Equity securities (1)725432362210692
Short-term investments——330257——330257
Derivative assets——81681,3319231,412991
Financial liabilities at fair value
Derivative liabilities$—$—$8$22$483$354$491$376

*(1)*Excludes certain equity securities that have no readily determinable fair value.

Level 3 Financial Assets and Financial Liabilities

Certain inputs for instruments classified in Level 3 are unobservable (supported by little or no market activity) and significant to their resulting fair value measurement. Unobservable inputs reflect the Company's best estimate of what hypothetical market participants would use to determine a transaction price for the asset or liability at the reporting date. Additionally, as discussed in Note 9E to the Consolidated Financial Statements in the Company's 2025 Form 10-K, the Company classifies variable annuity assets and liabilities in Level 3 of the fair value hierarchy.

Information about Debt Securities. The significant unobservable input used to value our corporate and government debt securities, and mortgage and other asset-backed securities, is an adjustment for liquidity. This adjustment is needed to reflect current market conditions and issuer circumstances when there is limited trading activity for the security.

The following table summarizes the fair value and significant unobservable inputs that were developed directly by the Company and used in pricing these debt securities. The range and weighted average basis point amounts for liquidity reflect the Company's best estimates of the unobservable adjustments a market participant would make to calculate these fair values. An increase in liquidity spread adjustments would result in a lower fair value measurement, while a decrease would result in a higher fair value measurement.

Fair Value as ofUnobservable Adjustment Range (Weighted Average by Quantity) as of
(Fair value in millions)September 30, 2026December 31, 2025Unobservable Input September 30, 2026September 30, 2026December 31, 2025
Debt securities
Corporate$240$286Liquidity60 - 920 (140)bps60 - 920 (175)bps
Mortgage and other asset-backed securities3138Liquidity115 - 340 (160)bps105 - 350 (160)bps
Other debt securities21
Total Level 3 debt securities$273$325

Information about Derivative Instruments. See Note 12A to the Consolidated Financial Statements in the Company’s 2025 Form 10-K for further information regarding our Level 3 derivative instruments.

Changes in Level 3 Financial Assets and Financial Liabilities Carried at Fair Value

The following table summarizes the changes in financial assets and financial liabilities classified in Level 3. Gains and losses reported in the table may include net changes in fair value that are attributable to both observable and unobservable inputs.

Three Months Ended September 30,Nine Months Ended September 30,
(In millions)2026202520262025
Beginning balance$1,052$362$896$417
Gains (losses) included in Shareholders' net income97(9)272(23)
(Losses) gains included in Other comprehensive (loss) income(14)21(15)31
Purchases, sales and settlements
Purchases1761767644
Sales—(1)(35)(3)
Settlements(27)(21)(29)(101)
Total purchases, sales and settlements(10)5953540
Transfers into / (out of) Level 3
Transfers into Level 31104159
Transfers out of Level 3(3)—(74)(45)
Total transfers into / (out of) Level 3(2)10(33)14
Ending balance$1,123$979$1,123$979
Total gains (losses) included in Shareholders' net income attributable to instruments held at the reporting date$97$(6)$272$(23)
Change in unrealized gain or (loss) included in Other comprehensive (loss) income for assets held at the end of the reporting period$(11)$11$(12)$18

Total gains and losses included in Shareholders' net income in the table above are reflected in the Consolidated Statements of Income as Net investment gains/losses and as Net investment income/losses. Gains and losses included in Other comprehensive (loss) income, net of tax, in the table above are reflected in Net unrealized appreciation (depreciation) on securities and derivatives in the Consolidated Statements of Comprehensive Income.

Transfers into or out of the Level 3 category occur when unobservable inputs, such as the Company's best estimate of what a market participant would use to determine a current transaction price, become more or less significant to the fair value measurement. Market activity typically decreases during periods of economic uncertainty, and this decrease in activity reduces the availability of market observable data. As a result, the level of unobservable judgment that must be applied to the pricing of certain instruments increases and is typically observed through the widening of liquidity spreads. Transfers between Level 2 and Level 3 during 2026 and 2025 primarily reflected changes in liquidity estimates for certain private placement issuers across several sectors. See discussion under Level 3 Financial Assets and Financial Liabilities above for more information.

Separate Accounts

The investment income and fair value gains and losses of Separate account assets generally accrue directly to the contractholders and, together with their deposits and withdrawals, are excluded from the Company's Consolidated Statements of Income and Cash Flows. The separate account activity for the nine months ended September 30, 2026 and 2025 was primarily driven by withdrawals and changes in the market values of the underlying separate account investments.

Fair values of Separate account assets were as follows:

Quoted Prices in Active Markets for Identical Assets (Level 1)Significant Other Observable Inputs (Level 2)Significant Unobservable Inputs (Level 3)Total
(In millions)September 30, 2026December 31, 2025September 30, 2026December 31, 2025September 30, 2026December 31, 2025September 30, 2026December 31, 2025
Guaranteed separate accounts (see Note 14)$246$247$321$330$—$—$567$577
Non-guaranteed separate accounts (1)2782715,6105,7691522096,0406,249
Subtotal$524$518$5,931$6,099$152$2096,6076,826
Non-guaranteed separate accounts priced at net asset value as a practical expedient (1)678661
Total$7,285$7,487

*(1)*Non-guaranteed separate accounts include $3.5 billion as of September 30, 2026 and $3.8 billion as of December 31, 2025 in assets supporting the Company's pension plans, including $0.1 billion classified in Level 3 as of September 30, 2026 and $0.2 billion as of December 31, 2025. Non-guaranteed separate accounts are primarily comprised of securities partnerships, real estate and real estate funds.

Separate account assets classified in Level 3 primarily support the Company's pension plans and include certain newly issued, privately placed, complex or illiquid securities that are priced using methods discussed above, as well as commercial mortgage loans. Activity, including transfers into and out of Level 3, was not material for the three and nine months ended September 30, 2026 or 2025.

**B.**Assets and Liabilities Measured at Fair Value under Certain Conditions

Some financial assets and liabilities are not carried at fair value, such as commercial mortgage loans that are carried at unpaid principal, investment real estate that is carried at depreciated cost and equity securities with no readily determinable fair value when there are no observable market transactions. However, these financial assets and liabilities may be measured using fair value under certain conditions, such as when investments become impaired and are written down to their fair value, or when there are observable price changes from orderly market transactions of equity securities that otherwise had no readily determinable fair value.

For the nine months ended September 30, 2026 and 2025, impairments recognized requiring the assets and liabilities described above to be measured at fair value were not material. Observable price changes for equity securities with no readily determinable fair value were not material for the nine months ended September 30, 2026 or 2025.

**C.**Fair Value Disclosures for Financial Instruments Not Carried at Fair Value

The following table includes the Company's financial instruments not recorded at fair value but for which fair value disclosure is required. In addition to universal life products and finance leases, financial instruments that are carried in the Company's Consolidated Balance Sheets at amounts that approximate fair value are excluded from the following table.

Classification in Fair Value HierarchySeptember 30, 2026December 31, 2025
(In millions)Fair ValueCarrying ValueFair ValueCarrying Value
Commercial mortgage loansLevel 3$1,137$1,202$1,195$1,233
Long-term debt, including current maturities, excluding finance leasesLevel 2$27,360$31,045$29,907$31,352

Note 11 – Accumulated Other Comprehensive Income (Loss)

Accumulated Other Comprehensive Income (Loss) ("AOCI") includes net unrealized appreciation/depreciation on securities and derivatives, change in discount rate and instrument-specific credit risk for certain long-duration insurance contractholder liabilities (see Note 7 to the Consolidated Financial Statements), foreign currency translation, and the net postretirement benefits liability adjustment. AOCI includes the Company's share from unconsolidated entities reported on the equity method. Generally, tax effects in AOCI are established at the currently enacted tax rate and reclassified to Shareholders' net income in the same period that the related pre-tax AOCI reclassifications are recognized.

Shareholders' other comprehensive (loss) income, net of tax, for the three and nine months ended September 30, 2026 and September 30, 2025 is primarily attributable to the change in discount rates for certain long-duration liabilities, including the impacts from unconsolidated entities reported on the equity method.

Changes in the components of AOCI were as follows:

Three Months Ended September 30,Nine Months Ended September 30,
(In millions)2026202520262025
Securities and derivatives
Beginning balance$714$1,053$594$832
Unrealized appreciation (depreciation) on securities and derivatives, before reclassification, net of tax (expense) benefit of $(14), $137, $(46) and $93, respectively10(406)126(237)
Amounts reclassified to Shareholders' net income, net of tax (benefit) of $—, $(1), $(1) and $(14), respectively15557
Other comprehensive income (loss), net of tax11(401)131(180)
Ending balance$725$652$725$652
Net long-duration insurance and contractholder liabilities measurement adjustments
Beginning balance$(3,976)$(2,815)$(2,329)$(2,038)
Net current period change in discount rate for certain long-duration liabilities, before reclassification, net of tax benefit (expense) of $38, $(146), $588 and $92, respectively(97)427(1,740)(296)
Amounts reclassified to Shareholders' net income, net of tax expense of $—, $—, $— and $16, respectively———(56)
Net current period change in discount rate for certain long-duration liabilities, net of tax benefit (expense) of $38, $(146), $588 and $108, respectively(97)427(1,740)(352)
Net current period change in instrument-specific credit risk for market risk benefits, net of tax benefit of $2, $2, $4 and $1, respectively(8)(6)(12)(4)
Other comprehensive (loss) income, net of tax(105)421(1,752)(356)
Ending balance$(4,081)$(2,394)$(4,081)$(2,394)
Translation of foreign currencies
Beginning balance$(175)$(120)$(127)$(198)
Net translation of foreign currencies, before reclassification, net of tax benefit (expense) of $—, $—, $2 and $(8), respectively(23)(10)(71)68
Ending balance$(198)$(130)$(198)$(130)
Postretirement benefits liability
Beginning balance$(924)$(934)$(944)$(937)
Amounts reclassified to Shareholders' net income, net of tax (benefit) of $(3), $(3), $(7) and $(7), respectively671919
Net change due to valuation update, before reclassification, net of tax benefit (expense) of $1, $1, $(2) and $4, respectively——7(9)
Other comprehensive income, net of tax672610
Ending balance$(918)$(927)$(918)$(927)
Total Accumulated other comprehensive loss
Beginning balance$(4,361)$(2,816)$(2,806)$(2,341)
Shareholders' other comprehensive (loss) income, net of tax benefit (expense) of $24, $(10), $538 and $177, respectively(111)17(1,666)(458)
Ending balance$(4,472)$(2,799)$(4,472)$(2,799)

Note 12 – Strategic Optimization Program

In the first quarter of 2025, the Company commenced an enterprise-wide initiative to evolve our business and deliver a more efficient and improved experience for our patients, providers and customers. The Company expects that the program will continue through 2028 and is continuing to evaluate additional opportunities to improve the overall efficiency and effectiveness of our operations. The program includes severance and other employee costs, asset impairments and accelerated asset amortization, and the operating results of certain small non-strategic businesses that we plan to discontinue.

During the three and nine months ended September 30, 2026, we reported total costs of $85 million ($62 million after-tax) and $535 million ($405 million after-tax), respectively, associated with this initiative, compared with $222 million ($168 million after-tax) and $566 million ($429 million after-tax), respectively, for the three and nine months ended September 30, 2025.

The total costs for the three and nine months ended September 30, 2026 included $86 million and $532 million, respectively, pre-tax in Selling, general and administrative expenses, which was primarily associated with severance ($61 million and $431 million, respectively). Comparatively, the total costs for the three and nine months ended September 30, 2025 included $181 million and $467 million, respectively, pre-tax in Selling, general and administrative expenses, which was primarily associated with severance ($141 million and $335 million, respectively).

Program-to-date total costs of $1,284 million pre-tax ($970 million after-tax) included $1,148 million in Selling, general and administrative expenses, which were primarily associated with severance ($809 million) and asset impairments ($109 million). The remainder of the total program costs reflects the operating results of certain non-strategic businesses. We expect substantially all of the accrued liability to be paid by the end of 2026. See Note 15 to the Consolidated Financial Statements for further details of the strategic optimization program by segment.

The following table presents a roll forward of the accrued liability recorded in Accrued expenses and other liabilities:

(In millions)
Balance, December 31, 2025$140
2026 charges431
2026 payments(372)
Balance, September 30, 2026$199

Note 13 – Income Taxes

Income Tax Expense. The effective tax rate of 19.1% for the three months ended September 30, 2026 was higher than the effective tax rate of 14.0% for the three months ended September 30, 2025. The increase was primarily driven by the absence of a prior-period benefit related to the HCSC transaction, the absence of prior-period benefits related to federal and state tax audits, and an increase related to the Company's equity method earnings. The effective tax rate of 18.0% for the nine months ended September 30, 2026 was higher than the effective tax rate of 15.9% for the nine months ended September 30, 2025. The increase was primarily due to the absence of a prior-period benefit related to the HCSC transaction and an increase related to the Company's equity method earnings.

Note 14 – Contingencies and Other Matters

The Company, through its subsidiaries, is contingently liable for various guarantees provided in the ordinary course of business.

**A.**Financial Guarantees: Retiree and Life Insurance Benefits

The Company guarantees that separate account assets will be sufficient to pay certain life insurance or retiree benefits. For the majority of these benefits, the sponsoring employers are primarily responsible for ensuring that assets are sufficient to pay these benefits and are required to maintain assets that exceed a certain percentage of benefit obligations. If employers fail to do so, the Company or an affiliate of the buyer of the retirement benefits business has the right to redirect the management of the related assets to provide for benefit payments. As of September 30, 2026, employers maintained assets that generally exceeded the benefit obligations under these arrangements of approximately $390 million. An additional liability is established if management believes that the Company will be required to make payments under the guarantees; there were no additional liabilities required for these guarantees, net of reinsurance, as of September 30, 2026. Separate account assets supporting these guarantees are classified in Levels 1 and 2 of the GAAP fair value hierarchy.

The Company does not expect that these financial guarantees will have a material effect on the Company's consolidated results of operations, liquidity or financial condition.

**B.**Certain Other Guarantees

The Company had indemnification obligations as of September 30, 2026 in connection with acquisition and disposition transactions. These indemnification obligations are triggered by the breach of representations or covenants provided by the Company, such as representations for the presentation of financial statements, filing of tax returns, compliance with laws or regulations, or identification of outstanding litigation. These obligations are typically subject to various time limitations, defined by the contract or by operation of law, such as statutes of limitation. In some cases, the maximum potential amount due is subject to contractual limitations based on a stated dollar amount or a percentage of the transaction purchase price, while in other cases limitations are not specified or applicable. The Company does not believe that it is possible to determine the maximum potential amount due under these obligations because not all amounts due under these indemnification obligations are subject to limitation. There were no recorded liabilities for these indemnification obligations as of September 30, 2026.

**C.**Guaranty Fund Assessments

The Company operates in a regulatory environment that may require its participation in assessments under state insurance guaranty association laws. The Company's exposure to assessments for certain obligations of insolvent insurance companies to policyholders and claimants is based on its share of business written in the relevant jurisdictions. There were no material charges or credits resulting from existing or new guaranty fund assessments for the nine months ended September 30, 2026.

**D.**Legal and Regulatory Matters

The Company is routinely involved in numerous claims, lawsuits, regulatory inquiries and audits, government investigations, including under the federal False Claims Act and state false claims acts initiated by a government investigating body or by a qui tam relator's filing of a complaint under court seal, and other legal matters arising, for the most part, in the ordinary course of managing a global health services business. Additionally, the Company has received and is cooperating with subpoenas or similar processes from various governmental agencies requesting information, all arising in the normal course of its business. Disputed tax matters arising from audits by the Internal Revenue Service or other state and foreign jurisdictions, including those resulting in litigation, are accounted for under GAAP guidance for uncertain tax positions.

Note 15 – Segment Information

See Note 1 to the Consolidated Financial Statements for a description of our segments. A description of our basis for reporting segment operating results is outlined below. Intersegment revenues primarily reflect pharmacy and care services transactions between the Evernorth Health Services and Cigna Healthcare segments. The President and Chief Executive Officer is the chief operating decision maker ("CODM") responsible for making decisions about resources to be allocated to each segment and assessing its performance.

The Company uses "pre-tax adjusted income (loss) from operations" and "adjusted revenues" as its principal financial measures of segment operating performance because management, including the CODM, believes these metrics reflect the underlying results of business operations and facilitate analysis of trends in underlying revenue, expenses and profitability to enable resource allocation decisions. We define pre-tax adjusted income (loss) from operations as income (loss) before income taxes excluding pre-tax income (loss) attributable to noncontrolling interests, net investment gains/losses, amortization of acquired intangible assets and special items. The Cigna Group's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting are also excluded. Special items are matters that management, including the CODM, believes are not representative of the underlying results of normal, recurring operations due to their nature or size. Adjusted income (loss) from operations is measured on an after-tax basis for consolidated results and on a pre-tax basis for segment results.

The Company defines adjusted revenues as total revenues excluding the following adjustments: special items and The Cigna Group's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting. Special items are matters that management, including the CODM, believes are not representative of the underlying results of normal, recurring operations due to their nature or size. We exclude these items from this measure because management, including the CODM, believes they are not indicative of past or future underlying performance of the business.

The Company does not report total assets by segment because this is not a metric used by the CODM to allocate resources or evaluate segment performance.

The following table presents the special items charges (benefits) recorded by the Company, as well as the respective financial statement line items impacted:

Three Months Ended September 30,Nine Months Ended September 30,
2026202520262025
(In millions)Pre-taxAfter-taxPre-taxAfter-taxPre-taxAfter-taxPre-taxAfter-tax
Strategic optimization program (primarily Selling, general and administrative expenses)$85$62$222$168$535$405$566$429
Charges (benefits) associated with litigation matters (Selling, general and administrative expenses)6049(17)(13)126101(17)(13)
Integration and transaction-related costs (Selling, general and administrative expenses)2317769270297226
Deferred tax expenses, net (Income taxes, less amount attributable to noncontrolling interests)—18—19—51—53
(Gain) on sale of businesses——(38)(241)(6)(6)(79)(356)
Total impact from special items$168$146$174$(61)$747$621$767$339

Summarized segment financial information was as follows:

(In millions)Evernorth Health ServicesCigna HealthcareOther OperationsCorporate and EliminationsTotal
Three months ended September 30, 2026
Revenues from external customers$63,347$10,001$48$—$73,396
Intersegment revenues4011,4186(1,825)
Net investment income26179748287
Total revenues63,77411,598128(1,817)73,683
Net investment results from certain equity method investments—110——110
Adjusted revenues$63,774$11,708$128$(1,817)$73,793
Pharmacy and other service costs60,519—
Medical costs—8,228
Selling, general and administrative expenses1,1472,290
Other segment items (1)
Interest (expense) and other13
Less: Income attributable to noncontrolling interests280—
Pre-tax adjusted income (loss) from operations1,8291,19322(394)2,650
Income (loss) before income taxes$1,608$946$24$(479)$2,099
Pre-tax adjustments to reconcile to adjusted income from operations
(Income) attributable to noncontrolling interests(280)———(280)
Net investment (gains) losses (2)(94)169(1)—74
Amortization of acquired intangible assets5872——589
Special items
Strategic optimization program816(1)6285
Charges associated with litigation matters—60——60
Integration and transaction-related costs———2323
Pre-tax adjusted income (loss) from operations$1,829$1,193$22$(394)$2,650
Other segment information
Depreciation and amortization$769$91$2$5$867

(1) Other segment items represent the difference between segment adjusted revenues less significant segment expenses and pre-tax adjusted income (loss) from operations, and they do not represent significant segment items relative to the CODM's review and oversight.

(2) Includes Net investment gains/losses as presented in our Consolidated Statements of Income, as well as the Company's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting, which are presented within Fees and other revenues in our Consolidated Statements of Income.

(In millions)Evernorth Health ServicesCigna HealthcareOther OperationsCorporate and EliminationsTotal
Three months ended September 30, 2025
Revenues from external customers$59,982$9,460$68$5$69,515
Intersegment revenues3801,35714(1,751)
Net investment income29116808233
Total revenues60,39110,933162(1,738)69,748
Net investment results from certain equity method investments—(178)——(178)
Adjusted revenues$60,391$10,755$162$(1,738)$69,570
Pharmacy and other service costs57,326—
Medical costs—7,579
Selling, general and administrative expenses1,0372,140
Other segment items (1)
Interest (expense) and other(2)2
Less: Income attributable to noncontrolling interests123—
Pre-tax adjusted income (loss) from operations$1,903$1,038$36$(399)$2,578
Income (loss) before income taxes$1,563$1,302$—$(570)$2,295
Pre-tax adjustments to reconcile to adjusted income from operations
(Income) attributable to noncontrolling interests(123)———(123)
Net investment losses (gains) (2)17(218)(5)2(204)
Amortization of acquired intangible assets4315——436
Special items
Strategic optimization program15441162222
Integration and transaction-related costs———77
(Benefits) associated with litigation matters—(17)——(17)
(Gain) on sale of businesses—(38)——(38)
Pre-tax adjusted income (loss) from operations$1,903$1,038$36$(399)$2,578
Other segment information
Depreciation and amortization$601$88$2$6$697

(1) Other segment items represent the difference between segment adjusted revenues less significant segment expenses and pre-tax adjusted income (loss) from operations, and they do not represent significant segment items relative to the CODM's review and oversight.

(2) Includes Net investment gains/losses as presented in our Consolidated Statements of Income, as well as the Company's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting, which are presented within Fees and other revenues in our Consolidated Statements of Income.

(In millions)Evernorth Health ServicesCigna HealthcareOther OperationsCorporate and EliminationsTotal
Nine months ended September 30, 2026
Revenues from external customers$182,630$30,308$146$—$213,084
Intersegment revenues9844,12516(5,125)
Net investment income7045721717761
Total revenues183,68434,890379(5,108)213,845
Net investment results from certain equity method investments—23——23
Adjusted revenues$183,684$34,913$379$(5,108)$213,868
Pharmacy and other service costs174,750—
Medical costs—24,053
Selling, general and administrative expenses3,2406,884
Other segment items (1)
Interest (expense) and other—7
Less: Income attributable to noncontrolling interests736—
Pre-tax adjusted income (loss) from operations4,9583,98370(1,208)7,803
Income (loss) before income taxes$4,592$3,735$58$(1,759)$6,626
Pre-tax adjustments to reconcile to adjusted income from operations
(Income) attributable to noncontrolling interests(736)———(736)
Net investment (gains) losses (2)(279)719(3)(202)
Amortization of acquired intangible assets1,3626——1,368
Special items
Strategic optimization program19513462535
Charges associated with litigation matters—126——126
Integration and transaction-related costs———9292
(Gain) on sale of businesses—(6)——(6)
Pre-tax adjusted income (loss) from operations$4,958$3,983$70$(1,208)$7,803
Other segment information
Depreciation and amortization$1,893$257$6$16$2,172

*(1)*Other segment items represent the difference between segment adjusted revenues less significant segment expenses and pre-tax adjusted income (loss) from operations, and they do not represent significant segment items relative to the CODM's review and oversight.

*(2)*Includes Net investment gains/losses as presented in our Consolidated Statements of Income, as well as the Company's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting, which are presented within Fees and other revenues in our Consolidated Statements of Income.

(In millions)Evernorth Health ServicesCigna HealthcareOther OperationsCorporate and EliminationsTotal
Nine months ended September 30, 2025
Revenues from external customers$169,470$31,986$260$5$201,721
Intersegment revenues2,3363,90139(6,276)
Net investment income9137622218707
Total revenues171,89736,263521(6,253)202,428
Net investment results from certain equity method investments—(272)——(272)
Adjusted revenues$171,897$35,991$521$(6,253)$202,156
Pharmacy and other service costs163,386—
Medical costs—25,446
Selling, general and administrative expenses3,1357,132
Other segment items (1)
Interest (expense) and other(1)6
Less: Income attributable to noncontrolling interests342—
Pre-tax adjusted income (loss) from operations5,0333,41961(1,192)7,321
Income (loss) before income taxes$4,101$3,764$(40)$(1,861)$5,964
Pre-tax adjustments to reconcile to adjusted income from operations
(Income) attributable to noncontrolling interests(342)———(342)
Net investment (gains) losses (2)(67)(285)22(348)
Amortization of acquired intangible assets1,26218——1,280
Special items
Strategic optimization program831499370566
Integration and transaction-related costs———297297
(Benefits) associated with litigation matters—(17)——(17)
(Gain) on sale of businesses(4)(75)——(79)
Pre-tax adjusted income (loss) from operations$5,033$3,419$61$(1,192)$7,321
Other segment information
Depreciation and amortization$1,772$252$13$16$2,053

*(1)*Other segment items represent the difference between segment adjusted revenues less significant segment expenses and pre-tax adjusted income (loss) from operations, and they do not represent significant segment items relative to the CODM's review and oversight.

*(2)*Includes Net investment gains/losses as presented in our Consolidated Statements of Income, as well as the Company's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting, which are presented within Fees and other revenues in our Consolidated Statements of Income.

Revenue from external customers includes Pharmacy revenues, Premiums, and Fees and other revenues. The following table presents these revenues by product, premium and service type:

Three Months Ended September 30,Nine Months Ended September 30,
(In millions)2026202520262025
Products (Pharmacy revenues) (ASC 606)
Network revenues$34,909$32,525$99,315$91,319
Home delivery and specialty revenues20,48520,51360,71759,424
Other revenues3,9723,40311,1189,913
Total Evernorth Health Services59,36656,441171,150160,656
Other Operations—14—41
Corporate and eliminations(384)(401)(959)(2,361)
Total Pharmacy revenues58,98256,054170,191158,336
Insurance premiums (ASC 944)
Cigna Healthcare
U.S. Healthcare
Employer insured5,0184,70515,00314,077
Medicare Advantage———2,363
Stop loss2,1911,9086,4455,655
Individual and Family Plans7967882,5292,588
Other5214881,5532,822
U.S. Healthcare8,5267,88925,53027,505
International Health1,1581,0473,4153,051
Total Cigna Healthcare9,6848,93628,94530,556
Other Operations5468162227
Corporate and eliminations14777449190
Total Premiums9,8859,08129,55630,973
Services (Fees) (ASC 606) and other revenues (1)
Evernorth Health Services4,3823,92112,46411,150
Cigna Healthcare1,7351,8815,4885,331
Other Operations———31
Corporate and eliminations(1,588)(1,422)(4,615)(4,100)
Total Fees and other revenues (1)4,5294,38013,33712,412
Total revenues from external customers$73,396$69,515$213,084$201,721

*(1)*Other revenues for the three months ended September 30, 2026 and 2025 were $60 million and $276 million, respectively, and for the nine months ended September 30, 2026 and 2025 were $534 million and $552 million, respectively.

Financial and performance guarantees. Evernorth Health Services may also provide certain financial and performance guarantees, including a minimum level of discounts a client may receive, generic utilization rates and various service levels. Clients may be entitled to receive compensation if we fail to meet the guarantees. Actual performance is compared to the contractual guarantee for each measure throughout the period, and the Company defers revenue for any estimated payouts within Accrued expenses and other liabilities (current). These estimates are adjusted and paid following the end of the annual guarantee period. Historically, adjustments to original estimates have not been material. This guarantee liability was $1.9 billion as of September 30, 2026 and $1.8 billion as of December 31, 2025.

Previous: Cover and table of contents · Next: Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS